Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Buy the dip in this major pharma stock - Citi
May 6, 2024 9:30 AM EDTCiti analysts said in a note Monday that they believe history shows the dip in one major pharmaceutical company's shares should be bought.
The investment bank said Novo Nordisk (NYSE: NVO) remains Buy-rated, while the firm also maintained a Dkr975.00 price target on the stock.... More
Novo Nordisk, Eli Lilly drop on Amgen competition concerns
May 3, 2024 7:15 AM EDT(Updated - May 3, 2024 7:48 AM EDT)
Shares of Novo Nordisk (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY) are down premarket Friday as competition in the GLP-1 market. Amgen (NASDAQ: AMGN) disclosed that it looked at AMG133's unblinded phase 2 interim trial and came away confident in 133's differentiated... More
Amgen (AMGN) PT Raised to $307 at UBS
May 3, 2024 7:06 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $307.00 (from $284.00) while maintaining a Neutral rating.
The analyst comments "The much anticipated MariTide interim completed (earlier than we expected) with mgmt providing positive qualitative commentary, as we had expected. At face... More
